29.14USD+1.36%Mkt Cap: 1.33B USDP/E: —Last update: 2026-05-26
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combin…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap1.33B USD
Enterprise Value1.02B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-161.15M USD
Revenue/Share—
Last Price29.14 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees133
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.54
PEG—
EV/EBITDA-4.88
EV/Revenue—
P/S—
P/B2.81
EPS (TTM)-4.41
EPS (Forward)-4.48
52W Range
12.2480% of range33.28
52W High33.28 USD
52W Low12.24 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-35.16%
ROA-33.61%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-138.14M USD
CapEx (TTM)473.00K USD
FCF Margin—
FCF Yield-7.17%
Net Debt-304.52M USD
Net Debt/EBITDA1.45
Balance Sheet
Debt/Equity0.01
Current Ratio22.91
Quick Ratio21.71
Book Value/Sh10.41 USD
Cash/Share6.839 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)36.00 USD
Target Range28.00 USD – 45.00 USD
# Analysts8
Ownership
Shares Out.42.62M
Float12.37M
Insiders51.16%
Institutions55.99%
Short Interest
Short Ratio5.4d
Short % Float7.93%
Short % Out.4.09%
Shares Short1.74M
Short (prev mo.)1.42M
Technical
SMA 5025.33 (+15.0%)
SMA 20020.09 (+45.1%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)279.31K
Avg Vol (10d)247.96K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—